Author: healthadmin
As artificial intelligence technology advances, many health systems are shifting their focus from AI tools focused on individual tasks to systems responsible for end-to-end operational workflows. Cleveland Clinic is working with startup Luminai to automate complex administrative tasks, starting with areas such as referral management. The Cleveland Clinic, one of the world’s largest academic medical centers, reported nearly 16 million patient visits in 2025. We serve patients in 23 hospitals and 300 outpatient facilities around the world, and referrals are often the starting point for their treatment. Processing referrals relies heavily on manual review of faxes and manual interpretation of…
Arvinas and Pfizer are the first to cross the FDA finish line with PROteoosis TArgeting Chimera (PROTAC) therapy, opening the door to a new option for certain breast cancer patients. However, the companies will no longer be involved as they seek a new partner to commercialize the drug following lackluster clinical data. The drug, called Veppanu (vepdegestrant), has received approval to treat adult patients with ER-positive, HER2-negative advanced or metastatic breast cancer with estrogen receptor 1 mutations after receiving at least one prior endocrine therapy. The agreement arrived one month before the FDA’s scheduled June 5 decision date. CEO Randy…
Get the latest news in health technology, digital health and health AI with this weekly overview. News for the week from April 27th to May 1st. AI tools can detect ADHD years before childhood diagnosis: study Artificial intelligence tools can analyze electronic health records (EHRs) and accurately estimate a child’s risk of developing attention-deficit/hyperactivity disorder (ADHD) before a typical diagnosis, a new Duke Health study finds. In the April 27 study, researchers analyzed the EHRs of more than 140,000 children with and without a diagnosis of ADHD. A specialized AI model was trained to examine the patient’s medical history and…
Recent research published in Economics and human biology suggests that carrying excess weight does not inherently reduce one’s chances of finding employment in Australia. After analyzing longitudinal data, researchers found no consistent evidence that overweight or obese people face widespread employment discrimination. The findings suggest that weight has little effect on current job prospects when past work experience is taken into account. Over the past few decades, obesity rates have increased significantly around the world. In Australia alone, approximately one in three adults will be classified as obese in 2022. This weight gain poses a variety of health risks, but…
For decades, a small program at the Environmental Protection Agency has performed the painstaking scientific work of assessing the toxicity of chemicals. As it is commonly known, the calculations made by IRIS scientists underpin a vast array of chemical regulations, permits, and other environmental regulations in the United States and abroad. Now, the Trump administration has indicated that its library of more than 500 chemical assessments is unreliable, opening the door to undermining hundreds of efforts to protect people from harmful chemicals at the state and federal level. Environmental scientists say long-established standards, such as the amount of arsenic allowed…
Taking common cholesterol-lowering drugs known as statins does not seem to affect the long-term risk of developing dementia in older people. Although these drugs do provide cardiac protection, they do not appear to provide secondary protection against cognitive decline. The results of a large-scale observational study were recently published in the journal Neurology. Statins are widely available prescription drugs designed to lower low-density lipoproteins. Medical professionals often refer to this particular fat as “bad” cholesterol. This is a waxy substance that circulates in the bloodstream and can build up inside the walls of arteries. When this buildup occurs, the arteries…
Paleontologists have discovered the fossilized jawbone of a previously unknown ancient animal in a dry riverbed deep in a forest near the Brazilian Amazon. As the excavation continued, the team discovered eight more similar jawbones, each about 6 inches long. However, no additional bones apparently consistent with a complete skeleton were recovered. Still, these isolated jaws revealed something remarkable. This fossil belongs to a species that lived about 275 million years ago, and would have been considered a “living fossil” even then. The jaw was also very unusual and had a twisted shape. Some of the teeth are oriented outward…
The union at fast-growing South Korean CDMO Samsung Biologics launched a planned general strike on Friday, intensifying a dispute that has been brewing over the past few months. The five-day strike is the first since the company was founded in 2011, and the union is demanding increases in base pay and performance-based wages, The Korea Herald reported on May 1. “At this time, Samsung Biologics’ priority is to maintain supply stability and minimize the impact,” a company spokesperson said in an emailed statement. “To reduce disruption, the company is deploying experienced personnel and those who have recently completed training to…
An unexpected missed interim study in ivonecicimab’s high-profile Harmoni-3 study has sent Summit Therapeutics’ stock price plummeting, clouding the company’s momentum as its star PD-1xVEGF bispecific drug heads into the ASCO annual meeting with a shot at plenary honors. In a recently added interim analysis, the Harmoni-3 squamous cohort clearly missed statistical significance in terms of progression-free survival (PFS). Summit announced Thursday that an independent data monitoring committee recommended that the study continue as planned and maintain a double-blind design. The trial is evaluating Merck & Co.’s Keytruda plus chemotherapy in combination with ivonecicimab and chemotherapy as a first-line treatment…
After a six-month pilot, Boston-based Beth Israel Lahey Health (BILH) is expanding Heidi’s AI writing technology to all physicians across its health system. The deployment follows a trial to bring AI scribe to 1,000 providers, the organizations said. 89% of people who adopted this tool said they were satisfied with the quality of their notes. 90% said they felt more present with their patients. 82% said their cognitive load was reduced, and 74% said their time outside of work hours was reduced. “If we stick to the end-user experience and focus on true adoption rather than forcing implementation, we can…